(21) revealed that the genetic silencing of RAC3 in bladder cancer cells increased their susceptibility to gemcitabine, suggesting that RAC3 could play a role in the progression of chemotherapy resistance in bladder cancer by modulating the immune microenvironment. The gene discussed is RAC3; the disease is urinary bladder cancer.